These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 16048150)
1. The importance of taking a second look at new medications. Weaver JM Anesth Prog; 2005; 52(2):49. PubMed ID: 16048150 [No Abstract] [Full Text] [Related]
2. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]
3. New use approved for Vioxx. FDA Consum; 2002; 36(4):3. PubMed ID: 12184302 [No Abstract] [Full Text] [Related]
4. What ails the FDA? Cohen FJ N Engl J Med; 2005 Jun; 352(24):2554. PubMed ID: 15962406 [No Abstract] [Full Text] [Related]
5. The pain game. Wadman M Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159 [No Abstract] [Full Text] [Related]
6. Coxibs and cardiovascular disease. Fitzgerald GA N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192 [No Abstract] [Full Text] [Related]
7. Raising the safety bar--the FDA's coxib meeting. Okie S N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221 [No Abstract] [Full Text] [Related]
8. [Alleviating pain and preventing inflammation with selective COX-2 inhibitors. Prescribing with confidence in the future]. MMW Fortschr Med; 2005 Mar; 147(9):12. PubMed ID: 15794346 [No Abstract] [Full Text] [Related]
9. Risk assessment, drug approval, and liability. Somberg JC Am J Ther; 2006; 13(3):181-2. PubMed ID: 16772756 [No Abstract] [Full Text] [Related]
10. The Vioxx debacle revisited. Good CB; Kelley CL Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902 [No Abstract] [Full Text] [Related]
11. Merck withdraws Vioxx; FDA issues public health advisory. FDA Consum; 2004; 38(6):11. PubMed ID: 15675020 [No Abstract] [Full Text] [Related]
12. New drug approvals in 1999. Wynn RL Gen Dent; 2000; 48(4):380-4. PubMed ID: 11199608 [No Abstract] [Full Text] [Related]
13. The lessons of Vioxx. Frazier KC N Engl J Med; 2005 Sep; 353(13):1420-1; author reply 1420-1. PubMed ID: 16192497 [No Abstract] [Full Text] [Related]
14. Drug safety. FDA panel urges caution on many anti-inflammatory drugs. Couzin J Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414 [No Abstract] [Full Text] [Related]
15. Risk stratification in decisions about nonsteroidal anti-inflammatory drug cotherapy. Am J Manag Care; 2001 Sep; 7(12 Suppl):S404-6. PubMed ID: 11570033 [TBL] [Abstract][Full Text] [Related]
16. New drug approvals in 2001. Wynn RL Gen Dent; 2002; 50(4):304-8, 310. PubMed ID: 12640845 [No Abstract] [Full Text] [Related]
17. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
18. The Vioxx debacle. Alpert JS Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713 [No Abstract] [Full Text] [Related]
19. FDA panel rules COX-2 pain drugs should remain on the market. Health News; 2005 Apr; 11(4):2. PubMed ID: 15818760 [No Abstract] [Full Text] [Related]
20. What ails the FDA? Gorelick KJ N Engl J Med; 2005 Jun; 352(24):2553-4. PubMed ID: 15958814 [No Abstract] [Full Text] [Related] [Next] [New Search]